Upload
Featured Recent Articles Topics Login Upload

Search Results for 'placebo mace'

placebo mace published presentations and documents on DocSlides.

Alpha Omega MACE: 14.0% with EPA-DHA vs. 13.8% with placebo (p = 0.93)
Alpha Omega MACE: 14.0% with EPA-DHA vs. 13.8% with placebo (p = 0.93)
by delcy
MACE: 13.2% with ALA vs. 14.5% with placebo (p = 0...
New Insights from EXSCEL
New Insights from EXSCEL
by pongre
M. Angelyn Bethel, MD. Associate Professor of Diab...
EDUCATIONAL SLIDE MODULES
EDUCATIONAL SLIDE MODULES
by dsuser1
Module D: . Evaluating CV safety and potential for...
CV safety & Outcome trials of
CV safety & Outcome trials of
by aaron
Oral . Antidiabetics. Adverse CV events led the F...
EDUCATIONAL SLIDE MODULES
EDUCATIONAL SLIDE MODULES
by cheryl-pisano
Module D: . Evaluating CV safety and potential fo...
A GLP-1 Receptor Agonist CV Outcomes Trial
A GLP-1 Receptor Agonist CV Outcomes Trial
by BadassBabe
Final Results. Background. Trends in the Prevalenc...
Cardiovascular outcomes
Cardiovascular outcomes
by lois-ondreau
Silvio E Inzucchi. Professor of . Medicine. , . Y...
Beyond A1c: Exploring the Expanding Role of Anti-Diabetic Agents
Beyond A1c: Exploring the Expanding Role of Anti-Diabetic Agents
by deena
Saidee Oberlander, PharmD, BCPS. Acute Care Pharma...
Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights from the EXSCEL Trial
Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights from the EXSCEL Trial
by relylancome
Robert J. Mentz, M. Angelyn Bethel, Peter Merrill,...
LDL Cholesterol Lowering with
LDL Cholesterol Lowering with
by shoffer
Evolocumab. and Outcomes in Patients with . Perip...